Unigene Laboratories, Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Unigene Laboratories, Inc.
RedHill On The Rise With Three Drugs And Potential COVID-19 Therapy
The Israeli biotech which is listed on the NASDAQ is in for a busy 2021 with strong marketing pushes for Movantik, Aemcolo and Talicia and completing a pivotal trial for COVID-19 hopeful opaganib.
FDA Keeps Calcitonin Products On The Market But Narrows Osteoporosis Claim
Saying its review found “no conclusive evidence of a causal relationship” between the products and cancer, agency is allowing continued marketing of Miacalcin and Fortical nasal sprays but limiting use to only those post-menopausal women for whom alternative treatments are not suitable.
Deals of the Week: Is Astex Settling For An Underpriced Buyout?
A new life sciences hedge fund operated by two former associates of activist investor Carl Icahn is challenging Otsuka’s takeover of cancer drug developer Astex. Also, Johnson & Johnson’s London Innovation Center announced four alliances, Celgene took another option on one of its investments and Takeda teamed up with New York research institutions to form a new discovery institute.
Enteris Begins Its Phoenix Story With Nordic Deal
Newly formed Enteris inks its first licensing deal as it tries to prove to potential partners that its technology can help company up-cycle old drugs and improve their patent life by making them orally available.
Company Information
- Industry
-
Pharmaceuticals
- Nutraceuticals
-
Drug Delivery
- Macromolecule
- Nasal
-
Biotechnology
- Large Molecule
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity